BioSpace News Archive

- Multiple key data read-outs expected for 2021, including the ARC-7 interim analysis in 2Q21 - Domvanalimab’s advancement into a registrational study coupled with recent IND clearance for AB308, Arcus’s FcR-enabled anti-TIGIT antibody, reinforces Arcus’s position as a leader in the anti-TIGIT field - Promising early data in first-line metastatic pancreatic cancer for AB680, the first small-molecule CD73 inhibitor to enter clinical development,

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2020.

Global Cord Blood Corporation, China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced its unaudited financial results for the third quarter and first nine months of fiscal 2021, ended December 31, 2020.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that senior management will participate in fireside chats at two upcoming virtual investor conferences:

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company’s Board of Directors has approved a second-quarter 2021 dividend of $0 .17 per share. The dividend will be paid on May 5, 2021, to shareholders of record as of April 21, 2021

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the 41st Annual Cowen Healthcare Conference on Wednesday, March 3, 2021, at 10:20 a.m. (EDT).

BrainChip Holdings Ltd, a leading provider of ultra-low power high performance artificial intelligence technology, announced progress in testing with the NaNose where patients’ exhaled breath samples were tested for COVID-19.

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older.

Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of nonalcoholic steatohepatitis (NASH), today announces the Investigational New Drug Application (IND) approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC41 oral tablet, a liver-targeted prodrug.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the fourth quarter and full year ended December 31, 2020.